Innate lymphoid cells (ILCs) are tissue-resident lymphocytes categorized on the basis of their core regulatory programs and the expression of signature cytokines. Human ILC3s that produce the cytokine interleukin-22 convert into ILC1-like cells that produce interferon-γ in vitro, but whether this conversion occurs in vivo remains unclear. In the present study we found that ILC3s and ILC1s in human tonsils represented the ends of a spectrum that included additional discrete subsets. RNA velocity analysis identified an intermediate ILC3-ILC1 cluster, which had strong directionality toward ILC1s. In humanized mice, the acquisition of ILC1 features by ILC3s showed tissue dependency. Chromatin studies indicated that the transcription factors Aiolos and T-bet cooperated to repress regulatory elements active in ILC3s. A transitional ILC3-ILC1 population was also detected in the human intestine. We conclude that ILC3s undergo conversion into ILC1-like cells in human tissues in vivo, and that tissue factors and Aiolos were required for this process. factor Aiolos played an integral role in this process and cooperated with T-bet to suppress expression of IL-22 and RORγt. Importantly, the ILC3-ILC1 intermediate populations were not confined to the tonsils, but were also found in the lamina propria of the human ileum, suggesting that ILC3-to-ILC1 plasticity is common to mucosal tissues.
I
nnate lymphoid cells (ILCs) are tissue-resident lymphocytes that lack antigen-specific receptors and produce defined cytokines early during the immune response against pathogens [1] [2] [3] . Their function is to immediately respond to pathogens and facilitate subsequent responses by antigen-specific T cells and B cells 4 . Three major groups of ILCs are distinguished by the signature cytokines they produce: ILC1s release interferon (IFN)-γ; ILC2s secrete interleukin (IL)-5 and IL-13; and ILC3s produce IL-22 and IL-17. Each ILC group responds to distinct stimuli: IL-12, IL-18 and IL-15 trigger ILC1s; IL-33, IL-25 and thymic stromal lymphopoietin (TSLP) trigger ILC2s; and IL-23 and IL-1β trigger ILC3s. ILC subtypes are also defined by distinct transcriptional programs and the specific transcription factors that instruct these programs: T-bet and Hobit are critical for ILC1s, high expression of the transcription factor GATA-3 regulates ILC2s, and RORγt and Ahr control ILC3 identity and function 5 . The three ILC modules mirror the functional polarization of CD4
+ T-helper (T H ) cells into T H 1, T H 2 and T H 17 cells. ILC diversity, however, extends beyond the strict definitions of ILC1s, ILC2s and ILC3s. Single-cell RNA sequencing (scRNA-seq) has indicated substantial transcriptional heterogeneity in ILCs 6, 7 . Moreover, ILCs have been proposed as being plastic 8 . This attribute, which has been extensively studied in T cells 9, 10 , facilitates the adaptation of immune responses in disparate tissues to diverse pathogenic stimuli. ILC plasticity was first observed in ILC3s in vitro 11, 12 . Human RORγt + ILC3s cultured in vitro with IL-2, IL-15 or IL-23 acquire ILC1-like features, such as the production of IFN-γ and the expression of the transcription factor T-bet 11, 13 . Fatemapping experiments in Rorc reporter mice have indicated that a subset of IFN-γ + ILC1s derive in part from Rorγt + ILCs. This subset, referred to as ex-ILC3s, requires a decrease in Rorγt [14] [15] [16] , along with a coordinate increase in T-bet [14] [15] [16] [17] and Notch signaling [17] [18] [19] [20] , for its generation. However, the extent and biological impact of human ILC3 plasticity in vivo, and the tissue factors that promote plasticity in humans, remain unresolved.
We hypothesized that, if conversion of ILC3s to ILC1s occurs in humans in vivo, transitional ILC populations with features of both ILC3s and ILC1s should be detectable. In human mucosaassociated lymphoid tissues, ILC3s and intraepithelial ILC1s are CD56 + NKp44 + , but can be distinguished by the expression of CD196 (CCR6) and CD103 (α E β 7 -integrin), respectively 11, 21 . In the present study, we show that flow cytometry, transcriptome profiling, mass spectrometry and scRNA-seq analyses identified additional ILC subsets, which lay between ILC3s and ILC1s. In vivo transfer experiments into a humanized mouse model demonstrated that ILC3s acquired transcription factors and cytokines characteristic of ILC1-like cells in a tissue-dependent fashion. The transcription (Fig. 1a) and were not considered for further transcriptional analyses. Thus, the ILC3-ILC1 spectrum in human tonsil was more heterogeneous than previously anticipated.
Results

Four subsets of ILCs are detected in human tonsils
ILC3b and ILC1b have intermediate gene expression signatures
Next, ILC3a, ILC3b, ILC1a and ILC1b were sorted from four human tonsils (see Supplementary Fig. 1 ) and their transcriptome profiles analyzed by microarray analysis. Hierarchical clustering of thousands of gene expression measurements distinguished two separate, but related, clusters of ILC3s (ILC3a and ILC3b) and ILC1s (ILC1a and ILC1b) (data not shown). In principal component analysis (PCA), the first principal component (PC1), which accounted for 73% of the variation, distinguished ILC3a, ILC3b, ILC1b and ILC1a, and highlighted differences between ILC3a and ILC1a (Fig. 2a) . PC1 values for ILC3b and ILC1b were intermediate between those for ILC3a and ILC1a (Fig. 2a) . The second principal component (PC2), which accounted for 10% of the variation, separated ILC1a from ILC1b and ILC3b from ILC3a; the third principal component (PC3) accounted for 5% of the variation and most likely reflected donor effects (Fig. 2a) . We identified 599 transcripts differentially expressed between ILC3a and ILC1a: ILC3a abundantly expressed known ILC3 genes, such as IL22, IL23R and IL1R1, whereas known ILC1 genes, such as IFNG, GZMK and CCL4, were more highly expressed by ILC1a (Fig. 2b) . Examination of the most differentially expressed genes across the four subsets revealed a gradient of expression, which placed the ILC3b and ILC1b transcriptomes between those of ILC3a and ILC1a (Fig. 2c) .
Within the ILC3 subsets, 93 transcripts were expressed at least twofold higher in ILC3a than in ILC3b (Fig. 2d) ; across all four subsets, expression of many of these transcripts was similar or lower in ILC1b and ILC1a than in ILC3b (Fig. 2e) . Conversely, many of the 69 transcripts that were expressed more than twofold higher in ILC3b than in ILC3a were more abundantly expressed in ILC1b and ILC1a than in ILC3b (Fig. 2e) . Within the ILC1 subsets, 105 transcripts were more highly expressed in ILC1a than in ILC1b, and expression of many of these genes was even lower in ILC3b and ILC3a than in ILC1b (Fig. 2e) . Moreover, most of the 76 transcripts that were more abundantly expressed in ILC1b than in ILC1a were more highly expressed in ILC3b and ILC3a (Fig. 2e) .
RNA-seq analysis of the same ILC3-ILC1 subsets indicated the increased expression of core ILC1a genes (KLRD1, TIGIT, CD247, CD244, GZMK, GZMB) in ILC3b as well as ILC3a genes (RORC, KIT, ICOS, IL1R1, IL2, IL7R) in ILC1b (see Supplementary Fig. 2 ), suggesting that ILC3b and ILC1b subsets expressed transcriptional signatures of both ILC1s and ILC3s. As RNA-seq detected more genes than microarray analysis, sets of genes were identified that were specifically enriched in either ILC1b (that is, FCRL2, ABCG1, RABAC1) or ILC3b (that is, SCAP, ZBTB24, S100A8), in addition to genes with graded expression within the ILC3-ILC1 spectrum (see Supplementary Fig. 2 ; data not shown).
Finally, intracellular staining was used to determine the expression of IL-22 and IFN-γ protein in sorted ILC3a, ILC3b, ILC1b and ILC1a after stimulation with phorbol 12-myristate 13-acetate (PMA) + ionomycin. Only ILC3a expressed IL-22 (Fig. 2f) . The percentage of IFN-γ + cells gradually increased from ILC3b and ILC1b to ILC1a (Fig. 2f) , consistent with the increased expression of an ILC1-like phenotype in these cells. Overall, these data suggested a spectrum of gene expression in which ILC3b and ILC1b had transcriptional programs that were intermediate between the program of ILC1a and that of ILC3a.
Expression of key proteins is graded across ILC3-ILC1 subsets
To understand how responsiveness to environmental stimuli and effector functions changed across the ILC3-ILC1 subsets, a search was made for cell surface receptors, soluble factors and lineagedefining transcription factors with expression modulated across these subsets. Transcripts that had decreasing expression from ILC3a to ILC1a encoded the cytokine receptors CD127 (IL7R), IL-1R (IL1R1) and CD117 (KIT) (Fig. 3a) , the costimulatory molecule ICOS and the inhibitory receptors CD33, CD31 (PECAM1) and CD200R1 (Fig. 3a) , the cytokines and chemokines IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF) (CSF2), 
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B cell activating factor (TNFSF13B), leukemia inhibitory factor and chemokine ligand (CCL) 20 ( Fig. 3b) , and the transcription factors RORγt (RORC), Ahr and Tox2 (Fig. 3c) . In contrast, transcripts that progressively increased expression from ILC3a to ILC1a encoded surface molecules indicative of transforming growth factor (TGF)-β imprinting, such as TIGIT and CD9 (Fig. 3a) ; cytokines and chemokines, such as IFN-γ, CCL3, CCL4 and CCL5 (Fig. 3b) ; granzymes and perforin (Fig. 3b) ; and the transcription factors T-bet (TBX21), Hobit (ZNF683) and Aiolos (IKZF3) (Fig. 3c) . Next, the transcriptional changes were validated by flow cytometry analysis of protein expression in tonsils from multiple donors (six to eight). This focused on cell surface and intracellular molecules for which validated antibodies were available. Among the proteins with progressively lower expression from ILC3a to ILC1a, the expression of CD127, CD117, ICOS, IL-1R, CD200R1, CD33 and CD31 (Fig. 3d,e) was validated. Among the proteins with incrementally increased expression from ILC3a to ILC1a, CD39, CD94, TIGIT, CD9, CD244 and SIRP-γ were consistent with the changes observed at the transcript level (Fig. 3f,g ).
In addition, analysis of the data indicated that ILC3a selectively expressed the calcium-binding protein S100A4 (Fig. 3a,d ,e), which is secreted and can upregulate β 1 -integrin expression on epithelial cells 23 . ILC1b and ILC1a expressed the activating receptor NKG2C (encoded by KLRC2), as well as the activating adapter CD247 (CD3ζ) (Fig. 3a,f,g ), the expression of which has been associated with memory or adaptive NK cells that are specific for human cytomegalovirus infection. It was concluded that several key markers of ILC3s were progressively downregulated from ILC3a to ILC3b to ILC1b to ILC1a; conversely, prototypical markers of ILC1s were gradually acquired in the same direction.
ILC3-ILC1 subsets are distinct from NK cells
To corroborate the variegated expression of ILC3 and ILC1 programs in the ILC subsets using an alternative approach, highdimensional profiling of CD56
+
NKp44
+ cells of isolated tonsils (six donors) was performed with an immunophenotyping panel of 36 markers, including CD56, NKp44, CD127, CD196 and CD161, which is expressed by all ILCs and NK cells 12 . Cells were clustered by a b c ILC3a_1  ILC3a_2  ILC3a_3  ILC3a_4  ILC3b_1  ILC3b_2  ILC3b_3  ILC1b_1  ILC1b_2  ILC1b_3  ILC1b_4  ILC1a_1  ILC1a_2  ILC1a_3  ILC1a_4   GZMA  GZMB  GZMK  GZMM  PRF1  FASLG  TNFSF10  IL22  TNFSF13B  CCL20  CSF2  LIF  IL26  LTA  LTA  LTA  LTB  APP  IFNG  CCL3  CCL5  CCL4   CCR6  CD300LF  IL7R  KIT  CD33  ACVR2A  LST1  IL1R1  ICOS  CD200R1  BLVRA  S100A4  PECAM1  IL4R  CXCR3  TIGIT  CD300A  SIRPG  CD244  KLRD1  KLRC2  KLRB1  NKG7  CD9  CD247   ILC3a_1  ILC3a_2  ILC3a_3  ILC3a_4  ILC3b_1  ILC3b_2  ILC3b_3  ILC1b_1  ILC1b_2  ILC1b_3  ILC1b_4  ILC1a_1  ILC1a_2  ILC1a_3  ILC1a_4   RORC  AHR  NR1D1  RUNX2  TOX2  TOX2  KLF11  ELK3  RBPJ  RBPJ  HOXA7  AFF3  MAF  TBX21  IRF8  MYC  NR4A2  ZBTB16  PRDM1  IER3  IER3  EOMES  IKZF3 ZNF683 ZEB2
Expression ( Significance was calculated using an ordinary, one-way analysis of variance (ANOVA), multiple comparison test with Prism v.7 software. *P ≤0.05; **P ≤0.001, ***P ≤0.005, ****P ≤0.0001. e,g, Data are mean ± s.d.
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Nature ImmuNology t-distributed stochastic neighbor embedding (t-SNE) using viSNE analysis 24 . Six major clusters of cells were identified, with ILC3a and ILC1a distinguishable at the opposite sides of the CD127 t-SNE map (Fig. 4a ). ILC3b and ILC1b subsets were identifiable within the CD103
+ population based on expression gradients of CD127 and CD94 (Fig. 4a) . Key cell surface markers (such as CD196 and CD117) decreased from ILC3a-ILC3b to ILC1b, whereas other markers (such as NKG2A) increased from ILC3a-ILC3b to ILC1b-ILC1a (Fig. 4a,b ). ILC3a contained both CD39
+ and CD39 − cells (Fig. 4a) . Although both subsets secreted IL-22 on IL-23 stimulation (data not shown), they may differ in their ability to degrade ATP, because CD39 is an ectonucleotidase. Two additional clusters of CD103 − cells were identified as 'others' . One was characterized by concomitant expression of CD127, CD117, CD94 and NKG2A, and the second expressed CD94, NKG2A and CD16 (Fig. 4a) . These features suggested that they, most probably, corresponded to blood CD56 bright and CD56 dim NK cells (Fig. 4a ) 25, 26 . The ILC3b and ILC1b subsets were even more clearly demarcated when the analysis was restricted to CD103
+ cells (Fig. 4c) . Thus, mass spectrometry analysis confirmed the resolution of four ILC1-ILC3 subsets that were distinct from conventional NK cells.
ILC3 subsets convert into ILC1 subsets
To further resolve the heterogeneity of tonsil ILC3s and ILC1s, ILC3a, ILC3b, ILC1b and ILC1a cells were sorted from the same tonsil and processed for scRNA-seq using the 10x Genomics platform. Two separate donors were processed in parallel and ~5,000-6,000 cells from each of the two donors were characterized. Unsupervised clustering by t-SNE in donor 1 identified nine discrete clusters based on the ten most differentially expressed genes (Fig. 5a,b) . Five ILC3 clusters expressed RORC, IL23R, KIT, CD300LF and IL7R. Among these, cluster 0 had a relatively large number of cells, whereas clusters 2, 3, 5 and 6 had fewer cells (Fig. 5a-c) . Cells in cluster 5 had high expression of genes encoding cytokines, including IL22, IL26 and CSF2 (Fig. 5b,c) , which suggests that it may comprise ILC3s that have been exposed to activating stimuli in vivo. The expression of actin cytoskeleton proteins in cluster 2 and l-selectin in cluster 6 ( Fig. 5b ) indicated that cells in these clusters may represent alternative activation states and/or reflect their location in different niches. A large ILC1a cluster (cluster 1) and a small ILC1a-related cluster (cluster 7) that expressed IFNG, TBX21, KLRD1 and CD160 (Fig. 5a-c) were identified. Cluster 7 was enriched in genes related to the cell cycle, including Ki67 (Fig. 5b,c) , reflecting the presence of proliferating ILC1s. Importantly, cluster 4 expressed CD300LF, IL7R and KLRD1, and represented a transitional population (Fig. 5b,c) that probably encompassed the ILC3b and ILC1b subsets. However, we did not distinguish two separate transitional populations (Fig. 5a-c) , most likely because ILC3b and ILC1b share many overlapping transcripts and the sequencing depth of scRNA-seq (~1,500 transcripts per cell) was insufficient to separate cells with small, graded differences in transcript expression. Finally, cluster 8 was enriched in transcripts characteristic of B cells (immunoglobulins, major histocompatibility complex (MHC) class II and other transcripts related to antigen presentation) (Fig. 5b) and, most likely, represented a minor contamination (~1.5%) with tonsillar B cells. Similar results were observed in cells isolated from donor 2 (see Supplementary Fig. 3 ).
Next, ILC trajectories and dynamics were analyzed using RNA velocity, a high-dimensional vector that predicts the future state of single cells based on intronic and exonic reads in the RNA-seq datasets 27 . Projecting the RNA velocity field for cells from donor 1 on to its t-SNE plot evinced a clear directional flow, originating from cells in the transitional cluster 4 toward cluster 1 (ILC1s) (Fig. 5d,e) . In addition, directional flow of some of the replicating MKI67 + cells in cluster 7 toward cluster 1 (Fig. 5d,e) indicated that these proliferating cells may be ILC1 precursors. Altogether, these data suggest that, within the ILC3−ILC1 subsets, an intermediate population, cluster 4, was converting into ILC1-like cells, whereas additional cell clusters, such as cluster 5, 2, 6 and 7, expressed unique transcripts, perhaps reflecting proliferation, location into a specific tissue niche or exposure to activating stimuli.
ILC3-ILC1 subsets have a graded capacity to secrete IFN-γ
To explore the plasticity of ILC3-ILC1 subsets by functional analyses, ILC3a, ILC3b, ILC1b and ILC1a were cloned from two donors by limiting dilution in the presence of irradiated allogeneic feeder cells, IL-2 and IL-23. Growing clones were stimulated with PMA + ionomycin on day 15 of culture and the production of IL-22 and IFN-γ was assessed in cells derived from over 200 clones from the 2 individual donors. Cloning efficiencies were similar for ILC3a, ILC1b and ILC1a, whereas the efficiency for ILC3b was generally lower (data not shown). Most ILC3a-derived clones contained IL-22
+ cells, IFN-γ + cells and a few cells producing both cytokines (Fig. 6a and see Supplementary Fig. 4 ). Rarely (3 of 64 clones, 4.6%), ILC3a-derived clones exclusively produced IFN-γ ( Fig. 6a ; data not shown). A similar trend was observed in cells derived from ILC3b, although clones that generated only IFN-γ + cells were slightly more frequent (5 of 36, 13.8%) ( Fig. 6a ; data not shown). Most ILC1b-derived clones produced IFN-γ and only a few contained IL-22
+ cells (4 of 57, 7%) ( Fig. 6a ; data not shown). ILC1a-derived clones exclusively produced IFN-γ (Fig. 6a) . The percentage of IL-22
+ cells progressively decreased from ILC3a-derived clones to ILC1a-derived clones, whereas the percentage of IFN-γ + cells followed the opposite pattern ( Fig. 6b and see Supplementary Fig. 4) . Overall, these data indicate that, although a certain percentage of cells in ILC3a-derived clones acquired the ability to produce IFN-γ, the number of IFN-γ + cells progressively increased from ILC3a to ILC3b to ILC1b, and that ILC1a clones were fully committed to IFN-γ production.
the microenvironment impacts ILC3a plasticity
Next, the ability of ILC3a to generate IFN-γ + cells after transfer in vivo was tested. Human ILC3a were sorted at high purity from tonsils, cultured for 10 days in IL-7 and stem cell factor (SCF) to ensure selective expansion of IL-7R + CD117 + cells, further amplified in vitro for 10-15 days to attain adequate numbers of cells and transferred into MISTRG-6-15 mice 28, 29 , which express human M-CSF, IL-3/GM-CSF, signal regulatory protein (SIRP) α, thrombopoietin (TPO), IL-6 and IL-15 on a Rag2
background (see Supplementary Fig. 5 ). Before transfer, ILC3a were Rorγt hi Aiolos low/− T-bet low/− by intracellular staining and produced mainly IL-22 when stimulated with PMA + ionomycin (see Supplementary Fig. 6a,b) . At day 19 and day 39 post-transfer, ILCs, identified by the expression of human CD45 and MHC-I, were detected in the spleen and liver, but not in the epithelium or lamina propria of the small intestine (see Supplementary Figs. 5 and 6c) , indicating that MISTRG-6-15 lacked host factors to support the migration of human ILC3s into these mucosal sites. The percentage of human ILCs recovered from the liver was four-to fivefold higher than in the spleen at any time point analyzed (see Supplementary  Figs. 5c and 6c ). Based on intracellular staining for transcription factors, adoptively transferred ILCs had higher expression of Aiolos and T-bet in spleen than ILCs in the liver at both day 19 and day 39 (see Supplementary Fig. 6d-f) . Spleen ILCs at day 39 expressed significantly more Aiolos and T-bet than ILCs at day 19 posttransfer (see Supplementary Fig. 6d-f) . Transferred ILCs produced significantly more IFN-γ and less IL-22 in the spleen than in the liver, and this difference was more pronounced at day 39 than at day 19 (see Supplementary Fig. 6g-i) . Altogether, these results indicate that human ILC3a transferred into humanized MISTRG-6-15 mice were more likely to acquire ILC1-like features in the spleen than in the liver, and that this process was time 
Aiolos and t-bet extinguish the ILC3 program
Next, it was investigated whether plasticity within the ILC3-ILC1 subsets was governed by transcription factors upregulated early during the ILC3 to ILC1-like cell transition. Transcripts for IKZF3, encoding Aiolos, a transcription factor of the Ikaros family 30 , were absent in tonsil ILC3a and detected in ILC3b, and had the highest expression in ILC1b and ILC1a (Fig. 3c and see Supplementary Fig. 2b ). Known targets of Aiolos, such as IRF8 and MYC 31, 32 , had the same expression pattern whereas TBX21, encoding T-bet, was expressed in ILC1b and increased in ILC1a (Fig. 3c) . Intracellular staining for transcription factors confirmed that Aiolos was expressed in ILC3b, whereas T-bet was detectable in ILC1b (Fig. 7a,b) . To test whether Aiolos and T-bet were involved in the ILC3 to ILC1-like transition, use was made of the ILC3-like mouse cell line MNK3 (ref. 33 ). Aiolos (MNK3-Aiolos), TSPYL1   PCDH9   TRA2A   HNRNPH1   CDC42   GZMA   GZMB   COTL1   CST7   HOPX   CD247   KLRD1   GNLY   NKG7   CCL5   ANXA1   IER2   JAML   PRR5   NFKBIA   JUN   TNFSF13B   S100A4   FXYD5   IL7R   TBX21  IKZF3  KLRD1  CD160  IFNG  CCL4   RORC  IL7R  CD300LF  IL22  CSF2  I L26   MKI67  CCR6  IL23R  IL2  TIGIT 
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T-bet (MNK3-T-bet) or both (MNK3-Aiolos + T-bet) were lentivirally or retrovirally expressed in a selected MNK3 clone (MNK3-control) (see Supplementary Fig. 7a,b) . MNK3-T-bet made slightly less IL-22 than MNK3-control in response to IL-23 + IL-1β stimulation by intracellular staining and ELISA (Fig. 7c,d ). However, production of IL-22 was even more reduced in MNK3-Aiolos + T-bet. MNK3-Aiolos cells did not produce more IFN-γ (data not shown) and did not secrete less IL-22 compared with MNK3-control (see Supplementary Fig. 7c,d ). MNK3-T-bet produced more IFN-γ than MNK3-control (Fig. 7e) . However, IFN-γ production occurred with a delayed kinetic (48 h post-stimulation) and required stimulation with IL-18 and IL-12 in addition to IL-23 ( Fig. 7e ; data not shown). Thus, Aiolos and T-bet cooperated to extinguish the ILC3 program, whereas T-bet alone induced production of IFN-γ.
To investigate whether expression of Aiolos directly repressed ILC3 genes, cut-and-run chromatin profiling 34 was performed for Aiolos and histone 3 lysine 27 acetylation (H3K27ac), a histone marker associated with transcriptional activity, in MNK3-Aiolos + T-bet, MNK3-T-bet and MNK3-control. Aiolos bound active regulatory elements (H3K27ac + peaks) near the ILC3 genes Il22 (Fig. 7f) and Rorc (see Supplementary Fig. 8a ) in MNK3-Aiolos + T-bet. In addition, there was a limited but significant reduction of expression of RORγt by intracellular staining in MNK3-Aiolos + T-bet cells compared with MNK3-T-bet or MNK3-control (see Supplementary Fig. 8b,c) . Aiolos binding in MNK3-Aiolos + T-bet was not detected at type 1 loci, such as Ifng and Eomes, in or near housekeeping genes, such as b2m and Suv39h2, or in MKNK3-control (see Supplementary   Fig. 8d,e) , suggesting that Aiolos selectively regulated ILC3-specific genes.
As IKZF (Ikaros family zinc finger) members suppress gene expression by changing the chromatin landscape via deacetylation of local histones 35 , we leveraged our H3K27ac data to directly measure Aiolos-induced deacetylation in MNK3-Aiolos + T-bet, MNK3-T-bet and MNK3-control. Quantification of H3K27ac in MNK3-T-bet and MNK3-Aiolos + T-bet indicated that the relative H3K27ac was reduced exclusively at positions showing Aiolos peaks in MNK3-Aiolos + T-bet ( Fig. 7f and see Supplementary  Fig. 8f ). To test whether Aiolos repressed human chromatin regions that transitioned from 'on' in ILC3s to 'off ' in ILC1s, we identified direct Aiolos-binding sites by running de novo motif prediction on Aiolos peaks detected in MNK3-Aiolos + T-bet. Similar to Ikaros (encoded by Ikzf1), Aiolos bound a TGTGGT motif (see Supplementary Fig. 8g ). To analyze evolutionary conservation, we identified IKZF-binding motifs in the IL22 and RORC loci. We compared ATAC-seq peaks (indicative of chromatin accessibility) from human tonsil ILC3s and intraepithelial ILC1s 22 with mouse H3K27ac peaks from MNK3 cells. Consistent with direct binding, Aiolos peaks and repression were predominantly localized at the conserved motifs (Fig. 7f and see Supplementary Fig. 8a ). Thus, Aiolos directly suppressed chromatin activity at mouse-humanconserved distal regulatory elements of genes encoding ILC3 cytokines and transcription factors.
Next, it was assessed which tissue factors were most likely to control the expression of Aiolos and T-bet. The expression of Aiolos, T-bet and RORγt was quantified by intracellular staining in . One donor representing two is shown. The significance was calculated using ordinary, one-way ANOVA, multiple comparison test with Prism v.7 software. *P ≤0.05, **P ≤0.001, ***P ≤0.005, ****P ≤0.0001.
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Nature ImmuNology a tonsil ILC3a expanded with IL-7 and SCF for 15-20 days, and subsequently stimulated with various cytokines for an additional 5-10 days. ILC3a cultured with TGF-β and IL-23 expressed more Aiolos and T-bet and less RORγt compared with cells exposed to IL-7 and SCF only (Fig. 7g) . TGF-β exposure alone was sufficient to partially induce Aiolos and downregulate RORγt (Fig. 7g) . These data collectively suggest that TGF-β and IL-23 could represent the tissue factors that would coordinately regulate the expression of Aiolos, T-bet and RORγt driving the transition of ILC3s to ILC1-like cells.
ILC3-ILC1 subsets are present in the gut lamina propria
To test whether the ILC3-ILC1 intermediate subsets could be detected in other mucosal tissues, we sorted CD3 -CD19 -cells from the lamina propria of ileal specimens derived from two patients with Crohn's disease (CD) and two control donors, and analyzed the cells by scRNA-seq using the 10x Genomics platform. We computationally merged the samples from all four donors and harmonized them to remove batch effects. We also computationally removed myeloid cells, mast cells and plasma cells, or other B cell-related clusters, based on transcripts known to be expressed by these cell types (that is, LILRB4, TPSB2, CD19, SDC1 and IGKC). On reclustering, the t-SNE plot showed ten discrete subsets of putative ILCs (Fig. 8a ), which were detected in both control donors and CD patients (Fig. 8b) . A heat map based on the most differentially expressed genes indicated a major ILC3 cluster (cluster 0), as well as smaller ILC3-related clusters (clusters 3, 5, 6 and 8), which selectively expressed MHC-II (HLA-DPA1), activation markers (CD69) or migration molecules (SELL) indicative of a specific state of activation or location (Fig. 8c) . The analysis detected two major clusters of ILC1s (clusters 2 and 1) and a smaller cluster of ILC1s (cluster 9) that expressed very high amounts of PRF1 and FCGR3A (Fig. 8c) , and may therefore be closer to NK cells than to ILCs. Between the ILC3 and ILC1 clusters a group of cells, cluster 4, could be distinguished, which coexpressed markers of ILC3s and ILC1s, such as IL7R, KIT, IL23R, KLRD1, NKG7, KLRC1, CCL5, XCL1 and XCL2 (Fig. 8d) . A small cluster of actively proliferating cells that mainly expressed ILC1 markers, such as KLRD1 and IFNG (cluster 7), was more abundant in CD patients than control samples (99 versus 26 cells) (Fig. 8e) . These data indicate that an intermediate subset,
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Unstim. Stim. Articles Nature ImmuNology coexpressing markers of ILC3s and ILC1s, could be detected in the lamina propria of human ileum.
Discussion
In the present study it was shown that ILC3s and intraepithelial ILC1s in the human tonsils represent the ends of a spectrum that includes additional ILC3-and ILC1-related subsets. The presence of these discrete subsets reflected, at least in part, functional plastic- FGFBP2  GZMH  FCGR3A  PRF1  LYZ  CTSH  GSN  COTL1  HLA−DPB1  HLA−DPA1  GPX1  HLA−DRB1  LGALS1  HIST1H4C  VIM  TUBB  HMGB2  HMGB1  HMGN2  H2AFZ  TUBA1B  STMN1  TXNIP  KLF6  TRAC  ANXA1  S100A6  CD3E  S100A4  CD3G  IL32  CD3D  HES1  EGR1  CXCL2  IER2  FOS  DUSP1  CD69  FOSB  JUN  GZMB  DUSP2  KLRC1  SELL  XCL1  GNLY  CTSW  HLA−DRA  LMNA  CD74  CCR7  RASD1  SPINK2  ITM2C  TOB1  SOX4  IGLC3  IGLC2  IGHM  IGHA2  IGKC  IGHA1  JCHAIN  GZMA  CD7  CCL4L2  CCL3  XCL2  CCL4  KLRF1  CMC1  CCL5  CST7  KLRD1  NKG7  ID2  TNFSF13B  ALDOC  NCOA7  TLE1  TNFRSF25  CD52  LTB  LST1  IL7R   0 TBX21  IKZF3  KLRD1  CD160  IFNG  CCL4  XCL2  XCL1   RORC  IL7R  CD300LF  IL22  IL26  KIT  CCR6  IL23R   NKG7  KLRC1  CCL5  TNFSF13B  LIF Articles Nature ImmuNology plasticity, it cannot be excluded that certain ILC subsets may directly derive from the differentiation of rare progenitor cells undetected in this study. Whether conversion within the ILC3-ILC1 subsets is uni-or bidirectional also requires further investigation. Previous studies have shown that the conversion of ILC3s into ILC1s requires a decrease in the expression of Rorγt 14 , along with a coordinate increase in T-bet [14] [15] [16] [17] and Notch signaling [18] [19] [20] . Hobit may also concur in the ILC3-to-ILC1 conversion, given its requirement for ILC1 development 36 . The results pinpointed a role for Aiolos in this process. First, expression of Aiolos and known Aiolos targets was detected in ILC3b whereas the expression of T-bet became apparent in ILC1b. In gain-of-function experiments, concomitant expression of Aiolos and T-bet was required in the MNK3 cell line, a surrogate for ILC3s, to suppress the ILC3 signature genes IL22 and RORC. Cut-and-run experiments in these cells showed that Aiolos bound active regulatory elements near the IL22 and RORC genes, whereas H3K27ac levels, indicative of active chromatin, were reduced at the same positions. Finally, ATAC-seq experiments indicated that Aiolos-driven repression marked evolutionarily conserved regulatory elements that transitioned from accessible in human ILC3s to inaccessible in human ILC1s. Thus, Aiolos suppressed chromatin activity at regulatory elements of conserved signature ILC3 genes. It is unclear why the repressive function of Aiolos requires T-bet. We postulate that T-bet may be important for inducing chromatin modifications that facilitate Aiolos recruitment and/or its repressor activity. This interaction may occur at certain loci that are enriched in DNA-binding motifs for T-bet and Aiolos. Aiolos promotes NK cell maturation in mice, thus corroborating a role for this transcription factor in the acquisition of a type 1 functional program in a different context 37 . In agreement with our data, a role for Aiolos in human ILC3 to ILC1-like plasticity was very recently reported 38 .
The results of the present study provide insights into the impact of tissue microenvironment in controlling ILC heterogeneity and diversity. Adoptive transfer of ILC3a in humanized mice showed that the ILC3-to-ILC1 transition was tissue dependent, because it occurred more effectively in the spleen than in the liver. TGF-β could be one of the tissue factors that could control transition. ILC1s express TGF-β-imprinted molecules, such as Aiolos, Hobit, CD103, CD9, CD39 and TIGIT. Thus, ILC3 transition to ILC1-like cells may reflect the adaptation of ILC3s to tissue niches that are enriched in TGF-β, such as the tonsil epithelial cell layer. The inflammatory cytokine IL-23 also contributes to the transition of human ILC3s to ILC1s in vitro 11 as well as mouse ILC3s to ILC1s in vivo 14 , although the mechanism remains unclear. It was found that IL-23 enhanced the capacity of TGF-β to induce both Aiolos and T-bet, which may depend on the IL-23-mediated activation of STAT3 and STAT4 (refs. 39, 40 ); both have been shown to bind the promoters of Aiolos and T-bet, respectively.
The integration of flow cytometry and mass cytometry provided useful criteria to distinguish ILC1s, ILC3s and intermediate ILC subsets from conventional NK cells, which has been problematic [41] [42] [43] [44] . Although ILC3s share several markers with CD56 bright NK cells, including CD127 and CD117 26, 43 , we found that ILC3s lacked CD94 and NKG2A, while uniquely expressing CD196, CD300LF and IL-22. Intraepithelial ILC1s and NK cells also have many markers in common and both produce IFN-γ 44 . However, ILC1s and ex-ILC3s uniquely expressed TGF-β-induced markers of tissue residency, such as CD103. Omics analyses of sorted ILC populations have also revealed novel facets of ILC biology. In addition to ILC3 subsets producing IL-22, IL-26 and GM-CSF, ILC3s produced IL-2, which may impact other immune cells, such as NK cells and T reg cells 45 . ILC3s also produced S100A4, which may modify the barrier function of mucosal surfaces by increasing the expression of β 1 -integrin 23 . Similar to ILC3s, ILC1s were also functionally heterogeneous and encompassed subsets that produced CCL3, CCL4, XCL1 and XCL2 chemokines. Thus, in addition to IFN-γ production, ILC1s may be important for attracting other immune cells into the tissue during a pathogenic insult, as has recently been proposed for tissue-resident T cells 46 . Beyond the tonsils, scRNA-seq of human intestinal samples from CD patients and controls revealed the presence of an intermediate ILC3-ILC1 cell population in the lamina propria of the ileum. It will be important to further characterize whether microbiome, inflammatory conditions that occur during CD or other conditions impact ILC3-ILC1 diversity and plasticity.
In conclusion, the present study shows that ILC3 conversion to an ILC1-like phenotype occurs in vivo in humans and reveals a role for Aiolos in this process; it also emphasizes the relevance of the tissue niche in creating a microenvironment that promotes ILC diversity and functional adaptation to local stimuli.
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Data analysis
Cell Ranger pipeline (https://support.10xgenomics.com /single-cell-gene-expression/software /over-view/welcome) was used to process Chromium single-cell RNA-seq output to align reads and generate gene-cell expression matrices. Briefly, short sequencing reads were aligned to the GRCh38 reference genome and Ensembl 41 transcriptome by STAR 42. The uniquely aligned reads were used to quantify gene expression levels for all Ensembl genes. Downstream analyses were performed by R software package Seurat (http://satijalab.org/ seurat/). ScRNA-seq downstream analysis. Downstream analyses were performed by R software package Seurat (http://satijalab.org/ seurat/). Raw reads in each cell were first scaled by library size and then log-transformed. To improve downstream dimensionality reduction and clustering, we first regressed out unwanted source of variation arising from the number of detected molecules. Then highly variable genes were identified and selected for PCA reduction of high-dimensional data. Based on elbow plot, the top 25 PCs were selected for unsupervised clustering of cells. The resolution in the FindClusters function in Seurat was set to 0.6 and the clustering results were shown in a t-SNE plot. Accordingly, the marker genes in each cluster were identified by t-test implemented in the Seurat v2.3 package. RNA velocity analysis was performed as described29 using the following pipelines: RNA velocity https://github.com/velocytoteam/velocyto.R; RNA velocity of single cells (https://www.nature.com/articles/s41586-018-0414-6. Quantification of spliced and unspliced reads https://github.com/hms-dbmi/dropEst/ dropEst: pipeline for accurate estimation of molecular counts in droplet-based single-cell RNA-seq experiments (https://genomebiology.biomedcentral.com/articles/10.1186/s13059-018-1449-6). Harmonization of gut samples from merged donors was performed as described ( https://doi.org/10.1101/461954). Microarray data were analyzed with GenePattern software (Broad Institute) and normalized by RMA. Differences in gene expression
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were visualized with the Multiplot Studio function of Gene Pattern. The appropriate reference for details is quoted. Statistics in Figure 3 and 7 were calculated by Prism 7.0 (graphPad Software). For bulk RNAseq analysis sequences were aligned and gene count tables were produced using STAR aligner. Differential expression was analyzed using DESeq2 R Package (Love et al., 2014) . Genes with a sum of less than 10 counts among all samples were excluded from analysis. Gene expression was modeled as a sum of the effects of the cell type and batch, ie. data of experiment. Differentially expressed genes were estimated by the Wald test and p-values were automatically adjusted by DESeq2 using independent filtering for an FDR of 0.05. Details of analysis are included in the Online Methods section.
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Sample size
Sample size was determined based on the complexity and cost of the experiments. For flow cytometry and mass-spectometry data 6-8 donors were analyzed. For scRNAseq 2 donors were analyzed.
Data exclusions For microarray analysis in Fig 2, 1 replicate from ILC3a , ILC1b, and ILC1a (replicate 2) was excluded as it showed the greatest variability. The RNA from this replicate also did not pass quality controls for hybridazion in ILC3b. In Figure 3 , however, all replicates are presented. For PCA analysis outliers were excluded.
Replication
The number of experiments performed for each panel is indicated in Figure legend 
Authentication
The authors confirmed IL-22 and IL-17 secretion upon stimulation with the appropriate cytokines.
Mycoplasma contamination
The cell line was not tested for Mycoplasma. The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Sample preparation is detailed in methods
Instrument
BD LSR Fortessa and BDX20 were used for analysis. BD FACSAria II was used for sorting ad described in methods.
Software
Data were acquired on BD DIVA software and analyzed by Flowjo.
Cell population abundance Cell sorting purity was between 98-99% in all experiments.
Gating strategy
A gate was first applied on lymphocytes by gating on FSC/SSC. Doublets were the removed by gating on FSC-W and SSC-W. CD3 and CD19 contaminating cells were remove prior to gating on CD56+ cells. Gating strategy is illustrated in Supplementary Figure  1 .
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
